RFA joins arsenal for breast cancer metastases in the liver
In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.
In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.
Researchers from 12 centers participating in the tumor radio-frequency ablation Italian network (TRAIN) treated 102 patients with breast cancer, using the ablation technique. Under ultrasound or CT guidance, they applied RFA to tumors ranging from 0.8 to 5 cm in diameter. Results were presented at the 2004 RSNA meeting.
Using the Kaplan-Meier method, the researchers reported survival rates ranging from 95.2% at one year to 29.8% at five years. They completed RFA of tumors in 91.2% of the patients after 121 treatment sessions, and the primary effectiveness rate on a lesion-by-lesion basis was 86.9.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
